Ginkgo Bioworks Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jason Kelly
- Full Time Employees
- 485
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 27 Drydock Avenue Boston MA United States of America 02210
- IPO Date
- Apr 19, 2021
- CIK
- 0001830214
- Website
- ginkgo.bio
- Similar Companies
- Business
- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) operates as a leading synthetic biology company that develops a cell programming platform enabling customers to engineer organisms for applications across pharmaceuticals, biotechnology, agriculture, industrial biotech, food and nutrition, consumer products, and biosecurity; its core offerings include cell engineering research and development solutions such as functional genomics, antibody developability services, artificial intelligence models, reconfigurable automation systems, strain improvement for optimized microorganism production, Ginkgo Enzyme Services encompassing novel enzyme discovery, high-expression host strains like methanol-free Pichia pastoris and low-viscosity Aspergillus niger, fermentation process development with Ambr 250 bioreactors, and manufacturing scale-up up to 3,000L capacity, as well as biosecurity services through Canopy for biomonitoring and genomic data generation and Horizon for digital surveillance and biothreat detection. Founded in 2008 and headquartered at 27 Drydock Avenue in Boston, Massachusetts, the company serves diverse industries including government and defense via its two main segments of Cell Engineering and Biosecurity, with operations centered in the United States and facilities supporting global partnerships. Recent developments include the launch of Ginkgo Enzyme Services to advance enzyme R&D for pharmaceuticals, diagnostics, food, agriculture, and materials through ultra-high-throughput screening and machine learning-guided protein design; a multi-year extension of its strategic partnership with Bayer, originally established in 2017, to develop microbial nitrogen fixation, biological crop protection, and carbon sequestration solutions for sustainable agriculture, with Bayer retaining commercialization rights; and prior acquisitions such as FGen AG's screening platform in 2022 and Reverie Labs platform in 2024 to enhance its bioengineering capabilities.
Company News
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
DNA X, Inc. Reports Second Quarter 2026 Financial Results
Andrea Guerra, Prada CEO, Says Craftsmanship Is ‘The DNA Of Everything'
Ginkgo Bioworks Q2 Earnings Call Highlights
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
UW Credit Union Selects DNA from Fiserv to Power its Next Stage of Growth
Kane Biotech Announces Engagement of DNA Advisors
Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters
Caxton Associates LLP Sells 103,802 Shares of Ginkgo Bioworks Holdings, Inc. $DNA
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think
FTAI Aviation: Innovation Is Their DNA
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights